GVAX vs. Placebo for MDS/AML After Allo HSCT

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01773395
Recruitment Status : Recruiting
First Posted : January 23, 2013
Last Update Posted : July 21, 2017
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
Vincent T. Ho, MD, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : July 2019
  Estimated Study Completion Date : January 2033